LRP1 expression in cerebral cortex, choroid plexus and meningeal blood vessels: Relationship to cerebral amyloid angiopathy and APOE status

Neuroscience Letters

Volumn 525, Issue 2, 2012, Pages 123-128

  Ruzali, Wan Adriyani W ^a   Kehoe, Patrick G ^a   Love, Seth ^a  

^a FRENCHAY HOSPITAL   (United Kingdom)

Author keywords

Alzheimer's disease; Apolipoprotein E; Cerebral amyloid angiopathy; Low density lipoprotein receptor related protein 1

Indexed keywords

APOLIPOPROTEIN E; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; MESSENGER RNA;

ALZHEIMER DISEASE; ARTICLE; AUTOPSY; BLOOD VESSEL; BRAIN CORTEX; CHOROID PLEXUS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; GENOTYPE; HUMAN; HUMAN TISSUE; MENINX; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; VASCULAR AMYLOIDOSIS;

ALZHEIMER DISEASE; APOLIPOPROTEINS E; CASE-CONTROL STUDIES; CEREBRAL AMYLOID ANGIOPATHY; CEREBRAL CORTEX; CHOROID PLEXUS; HUMANS; LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN-1; MENINGES; RNA, MESSENGER;

EID: 84865410560     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2012.07.065     Document Type: Article

References (44)

1. Akram A., Schmeidler J., Katsel P., Hof P.R., Haroutunian V. Association of ApoE and LRP mRNA levels with dementia and AD neuropathology. Neurobiology of Aging 2012, 10.1016/j.neurobiolaging.2011.1004.1010.
2. Aleshkov S., Abraham C.R., Zannis V.I. Interaction of nascent ApoE2, ApoE3, and ApoE4 isoforms expressed in mammalian cells with amyloid peptide β(1-40). Relevance to Alzheimer's disease. Biochemistry 1997, 36:10571-10580.
3. Alonzo N.C., Hyman B.T., Rebeck G.W., Greenberg S.M. Progression of cerebral amyloid angiopathy: accumulation of amyloid-β40 in affected vessels. Journal of Neuropathology and Experimental Neurology 1998, 57:353-359.
4. Arelin K., Kinoshita A., Whelan C.M., Irizarry M.C., Rebeck G.W., Strickland D.K., Hyman B.T. LRP and senile plaques in Alzheimer's disease: colocalization with apolipoprotein E and with activated astrocytes. Brain Research. Molecular Brain Research 2002, 104:38-46.
5. Bales K.R., Liu F., Wu S., Lin S., Koger D., DeLong C., Hansen J.C., Sullivan P.M., Paul S.M. Human APOE isoform-dependent effects on brain beta-amyloid levels in PDAPP transgenic mice. Journal of Neuroscience 2009, 29:6771-6779.
6. Bell R.D., Deane R., Chow N., Long X., Sagare A., Singh I., Streb J.W., Guo H., Rubio A., Van Nostrand W., Miano J.M., Zlokovic B.V. SRF and myocardin regulate LRP-mediated amyloid-beta clearance in brain vascular cells. Nature Cell Biology 2009, 11:143-153.
7. Bu G. Receptor-associated protein: a specialized chaperone and antagonist for members of the LDL receptor gene family. Current Opinion in Lipidology 1998, 9:149-155.
8. Bu G. Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nature Reviews Neuroscience 2009, 10:333-344.
9. Cam J.A., Bu G. Modulation of beta-amyloid precursor protein trafficking and processing by the low density lipoprotein receptor family. Molecular Neurodegeneration 2006, 1:8.
10. Causevic M., Ramoz N., Haroutunian V., Davis K.L., Buxbaum J.D. Lack of association between the levels of the low-density lipoprotein receptor-related protein (LRP) and either Alzheimer dementia or LRP exon 3 genotype. Journal of Neuropathology and Experimental Neurology 2003, 62:999-1005.
11. Chalmers K., Wilcock G.K., Love S. APOE epsilon 4 influences the pathological phenotype of Alzheimer's disease by favouring cerebrovascular over parenchymal accumulation of A beta protein. Neuropathology and Applied Neurobiology 2003, 29:231-238.
12. Chow N., Bell R.D., Deane R., Streb J.W., Chen J., Brooks A., Van Nostrand W., Miano J.M., Zlokovic B.V. Serum response factor and myocardin mediate arterial hypercontractility and cerebral blood flow dysregulation in Alzheimer's phenotype. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:823-828.
13. Deane R., Wu Z., Sagare A., Davis J., Du Yan S., Hamm K., Xu F., Parisi M., LaRue B., Hu H.W., Spijkers P., Guo H., Song X., Lenting P.J., Van Nostrand W.E., Zlokovic B.V. LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron 2004, 43:333-344.
14. Deane R., Sagare A., Hamm K., Parisi M., Lane S., Finn M.B., Holtzman D.M., Zlokovic B.V. apoE isoform-specific disruption of amyloid β peptide clearance from mouse brain. Journal of Clinical Investigation 2008, 118:4002-4013.
15. Donahue J.E., Flaherty S.L., Johanson C.E., Duncan J.A., Silverberg G.D., Miller M.C., Tavares R., Yang W., Wu Q., Sabo E., Hovanesian V., Stopa E.G. RAGE, LRP-1, and amyloid-beta protein in Alzheimer's disease. Acta Neuropathologica 2006, 112:405-415.
16. Herz J., Bock H.H. Lipoprotein receptors in the nervous system. Annual Review of Biochemistry 2002, 71:405-434.
17. Hollister R.D., Kisiel W., Hyman B.T. Immunohistochemical localization of tissue factor pathway inhibitor-1 (TFPI-1), a Kunitz proteinase inhibitor, in Alzheimer's disease. Brain Research 1996, 728:13-19.
18. Holtzman D.M., Bales K.R., Tenkova T., Fagan A.M., Parsadanian M., Sartorius L.J., Mackey B., Olney J., McKeel D., Wozniak D., Paul S.M., Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America 2000, 97:2892-2897.
19. Holtzman D.M., Fagan A.M., Mackey B., Tenkova T., Sartorius L., Paul S.M., Bales K., Ashe K.H., Irizarry M.C., Hyman B.T. Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model. Annals of Neurology 2000, 47:739-747.
20. Kang D.E., Pietrzik C.U., Baum L., Chevallier N., Merriam D.E., Kounnas M.Z., Wagner S.L., Troncoso J.C., Kawas C.H., Katzman R., Koo E.H. Modulation of amyloid β-protein clearance and Alzheimer's disease susceptibility by the LDL receptor-related protein pathway. Journal of Clinical Investigation 2000, 106:1159-1166.
21. Lee G., Pollard H.B., Arispe N. Annexin 5 and apolipoprotein E2 protect against Alzheimer's amyloid-beta-peptide cytotoxicity by competitive inhibition at a common phosphatidylserine interaction site. Peptides 2002, 23:1249-1263.
22. (-ΔΔC(T)) method. Methods 2001, 25:402-408.
23. Love S., Nicoll J.A., Hughes A., Wilcock G.K. APOE and cerebral amyloid angiopathy in the elderly. Neuroreport 2003, 14:1535-1536.
24. Matsui T., Ingelsson M., Fukumoto H., Ramasamy K., Kowa H., Frosch M.P., Irizarry M.C., Hyman B.T. Expression of APP pathway mRNAs and proteins in Alzheimer's disease. Brain Research 2007, 1161:116-123.
25. McCarron M.O., Nicoll J.A. High frequency of apolipoprotein E (2 allele is specific for patients with cerebral amyloid angiopathy-related haemorrhage. Neuroscience Letters 1998, 247:45-48.
26. McCarron M.O., Nicoll J.A., Stewart J., Ironside J.W., Mann D.M., Love S., Graham D.I., Dewar D. The apolipoprotein E (2 allele and the pathological features in cerebral amyloid angiopathy-related hemorrhage. Journal of Neuropathology and Experimental Neurology 1999, 58:711-718.
27. Mirra S.S., Heyman A., McKeel D., Sumi S.M., Crain B.J., Brownlee L.M., Vogel F.S., Hughes J.P., van Belle G., Berg L. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991, 41:479-486.
28. Nicoll J.A., Burnett C., Love S., Graham D.I., Ironside J.W., Vinters H.V. High frequency of apolipoprotein E (2 in patients with cerebral hemorrhage due to cerebral amyloid angiopathy. Annals of Neurology 1996, 39:682-683.
29. Nicoll J.A., Burnett C., Love S., Graham D.I., Dewar D., Ironside J.W., Stewart J., Vinters H.V. High frequency of apolipoprotein E (2 allele in hemorrhage due to cerebral amyloid angiopathy. Annals of Neurology 1997, 41:716-721.
30. Palmer J.C., Baig S., Kehoe P.G., Love S. Endothelin-converting enzyme-2 is increased in Alzheimer's disease and up-regulated by Aβ. American Journal of Pathology 2009, 175:262-270.
31. Pietrzik C.U., Busse T., Merriam D.E., Weggen S., Koo E.H. The cytoplasmic domain of the LDL receptor-related protein regulates multiple steps in APP processing. EMBO Journal 2002, 21:5691-5700.
32. Qiu Z., Strickland D.K., Hyman B.T., Rebeck G.W. Elevation of LDL receptor-related protein levels via ligand interactions in Alzheimer disease and in vitro. Journal of Neuropathology and Experimental Neurology 2001, 60:430-440.
33. Rebeck G.W., Reiter J.S., Strickland D.K., Hyman B.T., Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions. Neuron 1993, 11:575-580.
34. Rebeck G.W., Harr S.D., Strickland D.K., Hyman B.T. Multiple, diverse senile plaque-associated proteins are ligands of an apolipoprotein E receptor, the α2-macroglobulin receptor/low-density-lipoprotein receptor-related protein. Annals of Neurology 1995, 37:211-217.
35. W.A.W. Ruzali, P.G. Kehoe, S. Love, Influence of LRP-1 and apoE on Aβ uptake and toxicity to cerebrovascular smooth muscle cells. Journal of Alzheimer's Disease, in press.
36. Shibata M., Yamada S., Kumar S.R., Calero M., Bading J., Frangione B., Holtzman D.M., Miller C.A., Strickland D.K., Ghiso J., Zlokovic B.V. Clearance of Alzheimer's amyloid-β(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. Journal of Clinical Investigation 2000, 106:1489-1499.
37. Silverberg G.D., Messier A.A., Miller M.C., Machan J.T., Majmudar S.S., Stopa E.G., Donahue J.E., Johanson C.E. Amyloid efflux transporter expression at the blood-brain barrier declines in normal aging. Journal of Neuropathology and Experimental Neurology 2010, 69:1034-1043.
38. Tanzi R.E., Moir R.D., Wagner S.L. Clearance of Alzheimer's Aβ peptide: the many roads to perdition. Neuron 2004, 43:605-608.
39. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. Neurobiology and Aging 1997, 18:S1-S2. The National Institute on Aging and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease.
40. Ulery P.G., Beers J., Mikhailenko I., Tanzi R.E., Rebeck G.W., Hyman B.T., Strickland D.K. Modulation of β-amyloid precursor protein processing by the low density lipoprotein receptor-related protein (LRP). Evidence that LRP contributes to the pathogenesis of Alzheimer's disease. Journal of Biological Chemistry 2000, 275:7410-7415.
41. Veinbergs I., Van Uden E., Mallory M., Alford M., McGiffert C., DeTeresa R., Orlando R., Masliah E. Role of apolipoprotein E receptors in regulating the differential in vivo neurotrophic effects of apolipoprotein E. Experimental Neurology 2001, 170:15-26.
42. Wilhelmus M.M., Otte-Holler I., van Triel J.J., Veerhuis R., Maat-Schieman M.L., Bu G., de Waal R.M., Verbeek M.M. Lipoprotein receptor-related protein-1 mediates amyloid-β-mediated cell death of cerebrovascular cells. American Journal of Pathology 2007, 171:1989-1999.
43. Wu Z., Guo H., Chow N., Sallstrom J., Bell R.D., Deane R., Brooks A.I., Kanagala S., Rubio A., Sagare A., Liu D., Li F., Armstrong D., Gasiewicz T., Zidovetzki R., Song X., Hofman F., Zlokovic B.V. Role of the MEOX2 homeobox gene in neurovascular dysfunction in Alzheimer disease. Nature Medicine 2005, 11:959-965.
44. Zlokovic B.V. Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends in Neurosciences 2005, 28:202-208.